- A joint research initiative of BADAS and University of Oslo (UIO), Norway
- Study Place: Two Institutions of Diabetic Association of Bangladesh (BIRDEM, NHN)
- Study design: Randomized Control Trial
- Study duration: 18 months
- Funding: UIO & BADAS
- Status: complete
- Key points:
- First randomized control trial to prevent Type 2 Diabetes in Person with IGT in Bangladesh
- To assess the outcome of different intervention (lifestyle, metformin, and glibenclamide) models to prevent diabetes among the high-risk group in Bangladesh
- Total participants: 1200 IGT subjects
- Risk reduction: Metformin + Lifestyle: 74%; Glibenclamide + LS: 66; Only lifestyle: 60%
Diabetes Prevention Intervention Study (DPIS)
